Characteristics | n |
---|---|
n | 33 |
Male:female | 8:25 |
JIA category | |
Oligoarticular | 7 (21) |
RF− polyarticular | 11 (33) |
RF+ polyarticular | 1 (3.0) |
Psoriatic | 6 (18) |
ERA | 8 (24) |
No. previous rounds of IA CS injections | |
1 | 7 (21) |
2 | 18 (54) |
3 | 8 (24) |
Age at first IA IFX injection, yrs | 12 (2.9–18) |
No. bilateral IFX injections | |
1 | 5 (15) |
2 | 16 (48) |
3 | 7 (21) |
4 | 2 (6.1) |
5 | 1 (3.0) |
6 | 1 (3.0) |
7 | 1 (3.0) |
Interval between first and last injection, mos | 2 (0–12) |
Interval between first and last MRI, mos | 9 (2–27) |
Systemic medicines prior to first IA IFX dose | |
None | 1 (3.0) |
MTX alone | 2 (6.1) |
TNFi alone | 5 (15) |
TNFi + DMARD, MTX, or LEF* | 25 (76) |
LEF + ABA* | 1 (3.0) |
↵* One subject was treated with ETN followed by ABA; the sum of patients represented in this table is 34 because this 1 subject fell into 2 separate categories. JIA: juvenile idiopathic arthritis; RF: rheumatoid factor; ERA: enthesitis-related arthritis; IA: intraarticular; CS: corticosteroid; IFX: infliximab; MRI: magnetic resonance imaging; MTX: methotrexate; TNFi: tumor necrosis factor inhibitor; DMARD: disease-modifying antirheumatic drug; LEF: leflunomide; ABA: abatacept; ETN: etanercept.